<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:chebi fb="0" ids="50864">Thiazolidinediones</z:chebi> (TZDs) are relatively new agents for the treatment of type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>They act as <z:chebi fb="4" ids="48705">agonists</z:chebi> at the PPAR-gamma nuclear receptor and their therapeutic effects include decreased <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> and <z:e sem="disease" ids="C0020456" disease_type="Disease or Syndrome" abbrv="">hyperglycaemia</z:e>, an improved plasma <z:chebi fb="23" ids="18059">lipid</z:chebi>, <z:mp ids='MP_0001845'>inflammation</z:mp> and pro-coagulant profile, and amelioration of <z:hpo ids='HP_0000822'>hypertension</z:hpo>, <z:mp ids='MP_0002959'>microalbuminuria</z:mp> and <z:hpo ids='HP_0001397'>hepatic steatosis</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>The most common side effects of TZDs include <z:mp ids='MP_0005456'>weight gain</z:mp> and <z:hpo ids='HP_0000969'>oedema</z:hpo>, with occasional reports of <z:hpo ids='HP_0001635'>congestive heart failure</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CHF</z:e>) </plain></SENT>
<SENT sid="3" pm="."><plain>This review discusses the benefit-risk profile of TZDs in treating patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, with particular reference to the heart </plain></SENT>
<SENT sid="4" pm="."><plain>To provide context, we explore briefly the epidemiology and pathophysiology of <z:hpo ids='HP_0001635'>heart failure</z:hpo> in patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, touch on the association of <z:e sem="disease" ids="C0018799" disease_type="Disease or Syndrome" abbrv="">heart disease</z:e> and cardiovascular mortality with antihyperglycaemic treatment modalities other than TZDs, and then focus on the effects of TZDs on the heart, <z:e sem="disease" ids="C0850624" disease_type="Disease or Syndrome" abbrv="">cardiovascular risk factors</z:e> and outcomes </plain></SENT>
<SENT sid="5" pm="."><plain>We describe the cluster of host factors, which seems to predispose patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> to TZD-induced or TZD-exacerbated <z:hpo ids='HP_0000969'>oedema</z:hpo> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CHF</z:e> and then provide an overview of the putative mechanisms of these TZD-related side effects </plain></SENT>
<SENT sid="6" pm="."><plain>We also propose that certain <z:chebi fb="40" ids="35498">diuretics</z:chebi> (<z:chebi fb="0" ids="2639">amiloride</z:chebi> and <z:chebi fb="0" ids="9241">spironolactone</z:chebi>), by targeting the distal nephron that expresses PPARgamma in collecting duct cells, might be of benefit in ameliorating the fluid retention and <z:hpo ids='HP_0000969'>oedema</z:hpo> associated with TZDs </plain></SENT>
</text></document>